Tevogen Bio Holdings Inc. (G28.F)
- Previous Close
0.9660 - Open
0.9700 - Bid 0.9760 x --
- Ask 1.0250 x --
- Day's Range
0.9700 - 0.9860 - 52 Week Range
0.2360 - 2.7200 - Volume
120 - Avg. Volume
5 - Market Cap (intraday)
193.051M - Beta (5Y Monthly) -0.80
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date Aug 4, 2025 - Aug 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients. It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV-associated lymphomas. The company was founded in 2020 and is headquartered in Warren, New Jersey.
tevogen.comRecent News: G28.F
View MorePerformance Overview: G28.F
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: G28.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: G28.F
View MoreValuation Measures
Market Cap
189.13M
Enterprise Value
198.44M
Trailing P/E
2.91
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
3.52
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-578.29%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-31.28M
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
1.97M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-350.79k